CBS 2019
CBSMD教育中心
中 文

药物涂层球囊

Abstract

Recommended Article

The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic Results and 1-Year Clinical Outcomes Outcomes after drug-coated balloon treatment for patients with calcified coronary lesions Contemporary use of drug-coated balloons in coronary artery disease: Where are we now? Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention: A Feasibility Study Drug-eluting balloons in coronary interventions: the quiet revolution? Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort Changes in high-sensitivity troponin after drug-coated balloon angioplasty for drug-eluting stent restenosis

Review Article2018 Jan 1;3(1):87.

JOURNAL:JAMA Cardiol. Article Link

Coronary Computed Tomography–Based Fractional Flow Reserve A Rapidly Developing Field

Baumann S, Renker M, Schoepf UJ. Keywords: Coronary Computed Tomography; Fractional Flow Reserve

ABSTRACT


Coronary computed tomography angiography (cCTA)–based fractional flow reserve (FFR-CT) is an evolving technology of disruptive potential to noninvasively determine the hemodynamic significance of a coronary artery stenosis. The systematic review by Cook et alprovides an excellent overview on the status of this innovative method. In their Methods section, the authors mention the FFR-CT algorithm approved by the US Food and Drug Administration in late 2014. However, technology and evidence in this field are rapidly evolving, which adds new facets to their discussion.